{
    "root": "2e12ecaf-bd76-4586-bd97-fb41eb61713b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ofev",
    "value": "20250429",
    "ingredients": [
        {
            "name": "NINTEDANIB ESYLATE",
            "code": "42F62RTZ4G"
        }
    ],
    "indications": "ofev kinase inhibitor indicated adults : treatment idiopathic pulmonary fibrosis ( ipf ) ( 1.1 ) treatment chronic fibrosing interstitial lung diseases ( ilds ) progressive phenotype ( 1.2 ) slowing rate decline pulmonary function patients systemic sclerosis-associated interstitial lung disease ( ssc-ild ) ( 1.3 )",
    "contraindications": "recommended : 150 mg taken orally twice daily approximately 12 hours apart taken food . ( 2.2 ) recommended patients mild hepatic impairment ( child pugh ) : 100 mg taken orally twice daily approximately 12 hours apart taken food . ( 2.3 , 8.6 ) consider temporary dose reduction 100 mg , treatment interruption , discontinuation management . ( 2.4 , 5.2 , 5.3 , 6 ) prior treatment initiation , conduct liver function tests patients pregnancy test females reproductive potential . ( 2.1 , 5.2 , 5.4 )",
    "warningsAndPrecautions": "150 mg : brown , opaque , oblong , soft capsules marked dark gray boehringer ingelheim company symbol `` 150 `` . packaged hdpe bottles child-resistant closure , available follows : bottles 60 ndc : 0597-0145-60 100 mg : peach , opaque , oblong , soft capsules marked dark gray boehringer ingelheim company symbol `` 100 `` . packaged hdpe bottles child-resistant closure , available follows : bottles 60 ndc : 0597-0143-60",
    "adverseReactions": "none",
    "indications_original": "OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 )",
    "contraindications_original": "Recommended dosage: 150 mg taken orally twice daily approximately 12 hours apart taken with food. ( 2.2 ) Recommended dosage in patients with mild hepatic impairment (Child Pugh A): 100 mg taken orally twice daily approximately 12 hours apart taken with food. ( 2.3 , 8.6 ) Consider temporary dose reduction to 100 mg, treatment interruption, or discontinuation for management of adverse reactions. ( 2.4 , 5.2 , 5.3 , 6 ) Prior to treatment initiation, conduct liver function tests in all patients and a pregnancy test in females of reproductive potential. ( 2.1 , 5.2 , 5.4 )",
    "warningsAndPrecautions_original": "150 mg:  brown, opaque, oblong, soft capsules marked in dark gray with the Boehringer Ingelheim company symbol and \"150\". They are packaged in HDPE bottles with a child-resistant closure, available as follows:\n                  \n                     \n                     \n                     \n                        \n                           Bottles of 60\n                           NDC: 0597-0145-60\n                        \n                     \n                  \n                  100 mg:  peach, opaque, oblong, soft capsules marked in dark gray with the Boehringer Ingelheim company symbol and \"100\". They are packaged in HDPE bottles with a child-resistant closure, available as follows:\n                  \n                     \n                     \n                     \n                        \n                           Bottles of 60\n                           NDC: 0597-0143-60",
    "adverseReactions_original": "None"
}